93749-47-4

Usage

Uses

Used in Pharmaceutical Research:
4-(2,2-Diethoxy-ethoxy)-benzoic acid methyl ester is used as a precursor in the synthesis of various pharmaceutical drugs for its potential to contribute to the development of new drug molecules.
Used in Organic Synthesis:
In the field of organic synthesis, 4-(2,2-Diethoxy-ethoxy)-benzoic acid methyl ester is used as a building block for the creation of novel materials, highlighting its versatility in chemical reactions and compound formation.
Used in Polymer Chemistry:
4-(2,2-Diethoxy-ethoxy)-benzoic acid methyl ester is utilized in polymer chemistry as a component in the synthesis of new materials, indicating its potential in enhancing material properties and developing innovative applications.

Upstream product

• 99-76-3 methyl 4-hydroxylbenzoate 
• 2032-35-1 Bromoacetaldehyde diethyl acetal 

Downstream Products

• 124064-21-7 4-(2-oxo-ethoxy)-benzoic acid methyl ester 
• 1026066-45-4 C₃₉H₄₄ClNO₄Si 
• 934285-94-6 methyl 4-{2-[5-chloro-2-(2-hydroxyethyl)-1-isopropyl-1H-indol-3-yl]ethoxy}benzoate 
• 934285-96-8 methyl 4-[2-(5-chloro-1-isopropyl-2-{2-[(methylsulfonyl)oxy]ethyl}-1H-indol-3-yl)ethoxy]benzoate 
• 934285-98-0 methyl 4-{2-[2-(2-azidoethyl)-5-chloro-1-isopropyl-1H-indol-3-yl]ethoxy}benzoate 
• 1026412-73-6 C₂₃H₂₇ClN₂O₃ 
• 934286-00-7 methyl 4-[2-(2-{2-[(benzylsulfonyl)amino]ethyl}-5-chloro-1-isopropyl-1H-indole-3-yl)ethoxy]benzoate 
• 1026097-42-6 methyl 4-(2-{5-chloro-1-(3,4-dichlorobenzyl)-2-[2-(2,2-dimethyl-1,1-diphenylpropoxy)ethyl]-1H-indol-3-yl}ethoxy)benzoate 
• 1027233-82-4 C₂₇H₂₄Cl₃NO₄ 
• 934286-08-5 methyl 4-[2-(5-chloro-1-(3,4-dichlorobenzyl)-2-{2-[(methylsulfonyl)oxy]ethyl}-1H-indol-3-yl)ethoxy]benzoate 
• 934286-10-9 methyl 4-{2-[2-(2-azidoethyl)-5-chloro-1-(3,4-dichlorobenzyl)-1H-indol-3-yl]ethoxy}benzoate 
• 1026750-11-7 C₂₇H₂₅Cl₃N₂O₃ 
• 934286-12-1 methyl 4-{2-[2-{2-[(benzylsulfonyl)amino]ethyl}-5-chloro-1-(3,4-dichlorobenzyl)-1H-indole-3-yl]ethoxy}benzoate 
• 479422-23-6 methyl 4-[2-(5-chloro-2-methyl-1H-indol-3-yl)ethoxy]benzoate 

Relevant academic research and scientific papers

Copper-Catalyzed Ring Opening of Benzofurans and an Enantioselective Hydroamination Cascade

A copper(II) acetate/(R)-DTBM-SEGPHOS-catalyzed ring opening of benzofurans and enantioselective hydroamination cascade with dimethoxymethylsilane (DMMS) and hydroxylamine esters is described. Starting from readily available substituted benzofurans, a series of chiral N,N-dibenzylaminophenols, which are of high interest in pharmaceutical chemistry, were obtained with excellent enantioselectivities (up to 66 % yield, 94 % ee).

A Pincer Ruthenium Complex for Regioselective C-H Silylation of Heteroarenes

A pincer Ru(II) catalyst for the highly efficient undirected silylation of O- and S-heteroarenes with (TMSO)2MeSiH and Et3SiH is described, producing heteroarylsilanes with exclusive C2-regioselectivity, good functional-group tolerance, and high turnover numbers (up to 1960). The synthetic utility of the silylated products is demonstrated by Pd-catalyzed Hiyama-Denmark cross-coupling under mild conditions. One-pot, two-step silylation and coupling procedures have been also developed.

An efficient synthesis of Ecopladib

An efficient synthesis of Ecopladib, an indole inhibitor of cytosolic phospholipase A2α, is described. A new reaction involving indole C3 reductive alkylation using an acetal in the absence of water and a novel transformation of the C2 methyl t

Methods for the use of inhibitors of cytosolic phospholipase A2 in the treatment of thrombosis

This invention provides methods for the use of substituted indole compounds of the general formula: and pharmaceutically acceptable salt forms thereof. The invention provides methods for the use of the compounds in the treating or preventing thrombosis in a mammal, or preventing progression of symptoms of thrombosis.

INHIBITORS OF CYTOSOLIC PHOSPHOLIPASE A2

This invention provides chemical inhibitors of the activity of various phospholipase enzymes, particularly cytosolic phospholipase A2 enzymes (cPLA2), more particularly including inhibitors of cytosolic phospholipase A2 alpha enzymes (cPLAα). In some embodiments, the inhibitors have the Formula I: wherein the constituent variables are as defined herein.

Inhibition of cytosolic phospholipase A2α: Hit to lead optimization

Compound 1 was previously reported to be a potent inhibitor of cPLA 2α in both artificial monomeric substrate and cell-based assays. However, 1 was inactive in whole blood assays previously used to characterize cyclooxygenase and lipoxygenase inhibitors. The IC50 of 1 increased dramatically with cell number or lipid/detergent concentration. In an attempt to insert an electrophilic ketone between the indole and benzole acid moieties, we discovered that increasing the distance between the two moieties gave a compound with activity in the GLU (7-hydroxycoumarinyl-γ- linolenate) micelle assay, which contains lipid and detergent. Extensive structure-activity relationship work around this lead identified a potent pharmacophore for cPLA2α inhibition. The IC50s between the GLU micelle and rat whole blood assays correlated highly. No correlation was found for other parameters, including lipophilicity or acidity of the required acid functionality. Compounds 25, 39, and 94 emerged as potent, selective inhibitors of cPLA2α and represent well-validated starting points for further optimization.

2-Acylamino-4-phenylthiazole derivatives, preparation thereof and therapeutic application thereof

The invention relates to 2-acylamino-4-phenylthiazole derivatives of general formula (I): pharmaceutically acceptable acid-addition salts thereof, hydrates or solvates of such derivatives or such pharmaceutically acceptable acid addition salts, intermediates thereto, processes for the preparation thereof, and therapeutic application thereof.

Process for making an aldehyde

A process for making an aromatic aldehyde in which a sulfoxide is reacted with a dihalogenated aromatic compound in the absence of an effective amount of an activating reagent. The aldehyde may then be used to make other compounds, such as a compound that acts as a cPLA inhibitor.

N-Acyl-2-substituted-1,3-thiazolidines, a New Class of Non-narcotic Antitussive Agents: Studies Leading to the Discovery of Ethyl 2--β-oxothiazolidine-3-propanoate

The synthesis of a novel class of antitussive agents is described.The compounds were examined for antitussive activity in guinea pig after cough induction by electrical or chemical stimulation.Ethyl 2--β-oxothiazolidine-3-propanoate (BBR 2173, moguisteine, 7) and other structurally related compounds showed a significant level of activity, comparable to that of codeine and dextromethorphan.The compounds presented in this paper are characterized by the N-acyl-2-substituted-1,3-thiazolidine moiety, which is a novel entry in the field of antitussive agents.The serendipitous discovery of the role played by the thiazolidine moiety in the determining the antitussive effect promoted extensive investigations on these structures.This optimization process on N-acyl-2-substituted-1,3-thiazolidines led to the initial identification of 2--3--1,3-thiazolidine (18a) as an interesting lead compound.The careful study of the rapid and very complicated metabolism of 18a provided further insights for the design of newer related derivatives.The observation that the metabolic oxidation on the lateral chain's sulfur of 18a to sulfoxide maintained the antitussive properties suggested the introduction of isosteric functional groups with respect to the sulfoxide moiety.Subsequent structural modifications showed that hydrolyzable malonic residues in the 3-position of the thiazolidine ring were able to assure high antitussive activity.This optimization ultimately led to the selection of moguisteine (7) as the most effective and safest representative of the series.Moguisteine is completely devoid of unwanted side effects (such as sedation and addiction), and its activity was demonstrated also in clinical studies.